Novel Biomolecules in Targeted Cancer Therapy: a New Approach Towards Precision Medicine

Overview

Journal Med Oncol

Publisher Springer

Specialty Oncology

Date 2023 Oct 7

PMID 37804361

Authors

Sandra Kannampuzha

Reshma Murali

Abilash Valsala Gopalakrishnan

Anirban Goutam Mukherjee

Uddesh Ramesh Wanjari

Arunraj Namachivayam

Alex George

Abhijit Dey

Balachandar Vellingiri

Affiliations

Soon will be listed here.

Abstract

Cancer is a major threat to human life around the globe, and the discovery of novel biomolecules continue to be an urgent therapeutic need that is still unmet. Precision medicine relies on targeted therapeutic strategies. Researchers are better equipped to develop therapies that target proteins as they understand more about the genetic alterations and molecules that cause progression of cancer. There has been a recent diversification of the sorts of targets exploited in treatment. Therapeutic antibody and biotechnology advancements enabled curative treatments to reach previously inaccessible sites. New treatment strategies have been initiated for several undruggable targets. The application of tailored therapy has been proven to have efficient results in controlling cancer progression. Novel biomolecules like SMDCs, ADCs, mABs, and PROTACS has gained vast attention in the recent years. Several studies have shown that using these novel technology helps in reducing the drug dosage as well as to overcome drug resistance in different cancer types. Therefore, it is crucial to fully untangle the mechanism and collect evidence to understand the significance of these novel drug targets and strategies. This review article will be discussing the importance and role of these novel biomolecules in targeted cancer therapies.

Citing Articles

miRNA-Based Technologies in Cancer Therapy.

Pagoni M, Cava C, Sideris D, Avgeris M, Zoumpourlis V, Michalopoulos I J Pers Med. 2023; 13(11).

PMID: 38003902 PMC: 10672431. DOI: 10.3390/jpm13111586.

References

Dragojevic S, Ryu J, Raucher D . Polymer-Based Prodrugs: Improving Tumor Targeting and the Solubility of Small Molecule Drugs in Cancer Therapy. Molecules. 2015; 20(12):21750-69. PMC: 6331894. DOI: 10.3390/molecules201219804. View

Silverman G . Anti-CD20 therapy and autoimmune disease: therapeutic opportunities and evolving insights. Front Biosci. 2006; 12:2194-206. DOI: 10.2741/2222. View

Browning J . B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nat Rev Drug Discov. 2006; 5(7):564-76. DOI: 10.1038/nrd2085. View

Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C . Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005; 23(18):4117-26. DOI: 10.1200/JCO.2005.09.131. View

Gerber D . Targeted therapies: a new generation of cancer treatments. Am Fam Physician. 2008; 77(3):311-9. View

Romond E, Perez E, Bryant J, Suman V, Geyer Jr C, Davidson N . Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005; 353(16):1673-84. DOI: 10.1056/NEJMoa052122. View

Moore M, Goldstein D, Hamm J, Figer A, Hecht J, Gallinger S . Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007; 25(15):1960-6. DOI: 10.1200/JCO.2006.07.9525. View

Willett C, Boucher Y, Tomaso E, Duda D, Munn L, Tong R . Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004; 10(2):145-7. PMC: 2693485. DOI: 10.1038/nm988. View

Tanner J . Designing antibodies for oncology. Cancer Metastasis Rev. 2006; 24(4):585-98. DOI: 10.1007/s10555-005-6197-x. View

10.

Imai K, Takaoka A . Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer. 2006; 6(9):714-27. DOI: 10.1038/nrc1913. View

11.

Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C . Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002; 346(9):645-52. DOI: 10.1056/NEJMoa011573. View

12.

Kantarjian H, Cortes J, OBrien S, Giles F, Garcia-Manero G, Faderl S . Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood. 2002; 101(1):97-100. DOI: 10.1182/blood-2002-02-0545. View

13.

Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R . CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346(4):235-42. DOI: 10.1056/NEJMoa011795. View

14.

Motzer R, Hutson T, Tomczak P, Michaelson M, Bukowski R, Rixe O . Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356(2):115-24. DOI: 10.1056/NEJMoa065044. View

15.

Ducry L, Stump B . Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies. Bioconjug Chem. 2009; 21(1):5-13. DOI: 10.1021/bc9002019. View

16.

Kamath A . Translational pharmacokinetics and pharmacodynamics of monoclonal antibodies. Drug Discov Today Technol. 2016; 21-22:75-83. DOI: 10.1016/j.ddtec.2016.09.004. View

17.

Panowski S, Bhakta S, Raab H, Polakis P, Junutula J . Site-specific antibody drug conjugates for cancer therapy. MAbs. 2014; 6(1):34-45. PMC: 3929453. DOI: 10.4161/mabs.27022. View

18.

Hoffmann R, Coumbe B, Josephs D, Mele S, Ilieva K, Cheung A . Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs). Oncoimmunology. 2018; 7(3):e1395127. PMC: 5769674. DOI: 10.1080/2162402X.2017.1395127. View

19.

Lu J, Jiang F, Lu A, Zhang G . Linkers Having a Crucial Role in Antibody-Drug Conjugates. Int J Mol Sci. 2016; 17(4):561. PMC: 4849017. DOI: 10.3390/ijms17040561. View

20.

Peters C, Brown S . Antibody-drug conjugates as novel anti-cancer chemotherapeutics. Biosci Rep. 2015; 35(4). PMC: 4613712. DOI: 10.1042/BSR20150089. View